12 Health Care Stocks Moving In Tuesday's After-Market Session

Benzinga · 04/15 21:05
Gainers
- icad (NASDAQ:ICAD) stock moved upwards by 72.5% to $3.33 during Tuesday's after-market session. The company's market cap stands at $87.7 million.
- BioSig Technologies (NASDAQ:BSGM) shares increased by 17.69% to $0.69. The company's market cap stands at $16.5 million.
- Dogwood Therapeutics (NASDAQ:DWTX) stock rose 10.57% to $4.6. The company's market cap stands at $8.7 million.
- Iridex (NASDAQ:IRIX) shares rose 10.0% to $1.1. The market value of their outstanding shares is at $18.3 million.
- MetaVia (NASDAQ:MTVA) shares moved upwards by 9.38% to $0.89. The company's market cap stands at $7.6 million.
- Lineage Cell Therapeutics (AMEX:LCTX) shares increased by 8.41% to $0.47. The market value of their outstanding shares is at $106.1 million.
Losers
- Impact BioMedical (AMEX:IBO) shares decreased by 9.8% to $0.46 during Tuesday's after-market session. The company's market cap stands at $5.2 million.
- Entero Therapeutics (NASDAQ:ENTO) shares declined by 8.35% to $0.37. The company's market cap stands at $1.7 million.
- Sensei Biotherapeutics (NASDAQ:SNSE) stock fell 7.87% to $0.42. The market value of their outstanding shares is at $10.6 million.
- Salarius Pharmaceuticals (NASDAQ:SLRX) stock decreased by 6.96% to $0.67. The market value of their outstanding shares is at $1.1 million.
- Syra Health (NASDAQ:SYRA) shares declined by 6.89% to $0.19. The company's market cap stands at $2.2 million.
- Cue Biopharma (NASDAQ:CUE) shares declined by 6.25% to $0.74. The market value of their outstanding shares is at $46.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.